Bharat Biotech Vaccine
Fair Pharma Scorecard
Toetst farmaceutische bedrijven op mensenrechten.
Menu
Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.
The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.
The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.
Sinovac does not publish a global access plan for its product.
SinoVac does not commit to comply with human rights standards in relation to product development and marketing.
The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.
SinoVac does not commit to C-TAP or the MPP.
SinoVac has not made a commitment not to enforce patents
SinoVac has delivered 380 million doses to COVAX.
SinoVac has entered into a clinical development collaboration with Butantan in Brazil. Future agreements will include technology licensing and commercialization rights. Sinovac also has a fill-and-finish deal with Pharmaniaga in Malaysia.
The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.
[Only applies to therapeutics]
SinoVac’s agreement with the Butantan institute so far is a clinical development collaboration, but future agreements will include technology licensing and commercialization rights. The deal with Pharmaniaga is a local manufacturing agreement (fill-and-finish). Sinovac has plans to “select 10 countries for technology transfer as soon as possible”
SinoVac’s vaccine costs 5 US dollars per dose in Thailand and other South-East Asian countries. This rises to 38 USD in the Philippines, 14 USD in India, 17 USD in Indonesia, and around 30 USD for China and Thailand. Diplomatic ties seem to determine the price of the vaccines between LMICs, rather than their ability to pay.
Sinovac has signed supply agreements for 993.221.000 doses outside of China. 993.221.000 doses – 500.000 doses for Mauritius – 200.000 doses for Singapore – 7.500.000 doses for Hong Kong = 980.521.000 doses for LMICs /993.221.000 x 100 = +/-98.72 of doses sold to LMICs (does not include doses for China itself, but since China is a middle-income country this does not make any difference for the result).
No information has been found on this criterion.
No information has been found on this criterion.
The company should be as transparent as possible, by publishing its research and development costs, profit margin, average costs of production, and production capacity for its Covid-19 product. It should also disclose the amount of public subsidies received during product development and/or testing. Licensing agreements should also be made publicly available and clinical trials should be registered in public repositories.
SinoVac has only published its financial reports up to 2018.
SinoVac has not published its profit margin for the vaccine. See T1.
SinoVac has not published the average and/or marginal costs of production for its vaccine.
SinoVac expects to produce 2 billion doses per year.
SinoVac’s vaccine appears to have been developed using private funds:
It received 15 million from Advantech Capital & Vivo Capital, 500 million USD from medical research firm
SinoVac has, however, not made any official statement on funding
No licensing agreements for Sinovac’s vaccine have been found online.
Yes, Sinovac registers its clinical trials on clinicaltrials.gov
Blijf op de hoogte van het werk van stichting Farma ter Verantwoording!
